Defining Incidence, Risk Factors, and Impact on Survival of Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome
| Autor: | Alexander Copelan, Thomas G. Fraser, Brian J. Bolwell, Housam Haddad, Rabi Hanna, Matt Kalaycio, Muhammad Omer Zaman, Edward A. Copelan, Mikkael A. Sekeres, Hien K. Duong, Ronald Sobecks, Lisa Rybicki, Joshua Lukenbill, Megan DiGiorgio, Brian T. Hill |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Adult
Male Catheterization Central Venous medicine.medical_specialty Myeloid Adolescent Umbilical cord Young Adult Sepsis Internal medicine hemic and lymphatic diseases Humans Medicine Survival analysis Aged Retrospective Studies Transplantation Acute myeloid leukemia Hematopoietic cell transplantation business.industry Incidence Incidence (epidemiology) Central line associated blood stream infections Hematopoietic Stem Cell Transplantation Myeloid leukemia Hematology Middle Aged medicine.disease Survival Analysis Surgery Leukemia Myeloid Acute Leukemia Treatment Outcome medicine.anatomical_structure Risk factors Catheter-Related Infections Myelodysplastic Syndromes Female Bone marrow business Myelodysplastic syndrome |
| Zdroj: | Biology of Blood and Marrow Transplantation. (5):720-724 |
| ISSN: | 1083-8791 |
| DOI: | 10.1016/j.bbmt.2013.01.022 |
| Popis: | Central line-associated blood stream infections (CLABSI) commonly complicate the care of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after allogeneic stem cell transplantation (HCT). We developed a modified CLABSI (MCLABSI) definition that attempts to exclude pathogens usually acquired because of disruption of mucosal barriers during the vulnerable neutropenic period following HCT that are generally included under the original definition (OCLABSI). We conducted a retrospective study of all AML and MDS patients undergoing HCT between August 2009 and December 2011 at the Cleveland Clinic (N = 73), identifying both OCLABSI and MCLABSI incidence. The median age at transplantation was 52 years (range, 16 to 70); 34 had a high (≥3) HCT comorbidity index (HCT-CI); 34 received bone marrow (BM), 24 received peripheral stem cells (PSC), and 15 received umbilical cord blood cells (UCB). Among these 73 patients, 23 (31.5%) developed OCLABSI, of whom 16 (69.6%) died, and 8 (11%) developed MCLABSI, of whom 7 (87.5%) died. OCLABSI was diagnosed a median of 9 days from HCT: 5 days (range, 2 to 12) for UCB and 78 days (range, 7 to 211) for BM/PSC (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|